Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BV211 in Adult Volunteers
NCT05718037Phase 1Unknown
- Sponsor
- Wuhan BravoVax Co., Ltd
- Start
- Aug 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, single-blind trial of BV211 in herpes zoster (HZ) (6 arms), sponsored by Wuhan BravoVax Co., Ltd. Primary endpoints: Safety in terms of adverse reactions/events, Safety in terms of laboratory-based AEs and 2 more. Status: unknown.
02
Drugs
BV211
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05718037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718037.